entertainment -WSS

entertainment

author：explore 2025-09-30 11:58:32 - browse：4432

Christopher Boerner -- biotech JPM coverage from STAT — Bristol CEO Christopher Boerner Business Wire via AP

SAN FRANCISCO — Christopher Boerner has been the CEO of Bristol Myers Squibb for just two months. But in trying to sell the company to investors on Monday at the annual J.P. Morgan Healthcare Conference, he pointed to the company’s 150-year history.

He spoke of the “next chapter” for BMS, which saw its stock fall 27% last year, and said that the company would be going through a “period of renewal.” Basically, the tide comes in, but it also goes out. Patents on big-selling medicines expire, but new medicines will come to take their place.

Investors may not be able to view those changes with equanimity. Sales of Bristol’s top sellers will decline significantly or vanish as generic or biosimilar medicines emerge. That includes Eliquis, the blood thinner for stroke prevention that will be one of the first medications subject to price negotiation under the Inflation Reduction Act; Revlimid, the best-selling multiple myeloma medicine that Bristol acquired when it bought Celgene for $74 billion in 2019; and Opdivo, Bristol’s pioneering cancer immunotherapy, which is an $8 billion seller.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： H.R. 3 is the wrong path to lower drug costs

leisure time

WSS

Flint parents haunted by uncertainty, fears of lead poisoning

Physicians aren't 'burning out.' They're suffering from moral injury

Biotech startup Celsius cuts 75% of staff ahead of first trial start

Websites selling Wegovy, Zepbound ingredients targeted by FDA

AMAs digital advisors table RPM coding reform proposal, again

Chris Christie meets with Zelenskyy during Ukraine trip

explore

entertainment

knowledge

Guidelines to prevent youth baseball injuries need more muscle

Eli Lilly reports tirzepatide MASH success during Q4 earnings

How to save PrEP access — and even expand it

Having children helps parents live longer, especially after age 80

As demand for Covid shots wanes, Moderna seeks its next success

It costs an awful lot of money to give away a kidney

The cancer drug shortage isn’t new — and neither are the solutions

CDC recommends RSV monoclonal antibody for infants

Apple is now the first public company to be valued at $3 trillion

Readout Newsletter: Replicate, Biogen's Leqembi, and Humira

leisure time

The cancer stories no one wants to hear

Pharma showers House GOP doctor with campaign cash

Having children helps parents live longer, especially after age 80

AMAs digital advisors table RPM coding reform proposal, again

Study links childhood stress with decline in older age

H.R. 3 is the wrong path to lower drug costs

Wikipedia

focus

leisure time

leisure time